No­var­tis plots new Plu­vic­to fil­ing time­line af­ter wait­ing for over­all sur­vival re­sults

No­var­tis said Thurs­day in a brief, five-sen­tence press re­lease that it plans to file for an ex­pand­ed la­bel for its prostate can­cer treat­ment Plu­vic­to in the sec­ond half of this year. The ex­pand­ed la­bel could po­ten­tial­ly make the ra­dio­phar­ma­ceu­ti­cal avail­able to two to three times the num­ber of pa­tients for whom it’s cur­rent­ly ap­proved.

The an­nounce­ment comes af­ter the phar­ma de­layed its fil­ing plans in Oc­to­ber be­cause at the time, the key study un­der­pin­ning its ap­pli­ca­tion did not show a clear sur­vival ben­e­fit.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER